Qinlock is a drug owned by Deciphera Pharmaceuticals Llc. It is protected by 36 US drug patents filed from 2020 to 2024 out of which none have expired yet. Qinlock's patents have been open to challenges since 15 May, 2024. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 06, 2042. Details of Qinlock's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8461179 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
May, 2034
(9 years from now) | Active |
| US8188113 | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(5 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11779572 | Methods of treating gastrointestinal stromal tumors |
Oct, 2042
(17 years from now) | Active |
| US11969414 | Methods of treating gastrointestinal stromal tumors |
Feb, 2041
(16 years from now) | Active |
| US11903933 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11844788 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11911370 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11850240 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11850241 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11395818 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11612591 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11185535 | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | Active |
| US11793795 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US12064422 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11969415 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11801237 | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | Active |
| US12023328 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11896585 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11918564 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | Active |
| US11576903 | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | Active |
| US11576904 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11426390 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11433056 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11529336 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11534432 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11813251 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11344536 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US11266635 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US10966966 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US12059411 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US12059410 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US12023327 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US12023326 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US12023325 | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(15 years from now) | Active |
| US8940756 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(7 years from now) | Active |
| USRE48731 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qinlock's patents.
Latest Legal Activities on Qinlock's Patents
Given below is the list of recent legal activities going on the following patents of Qinlock.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11903933 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11896585 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11844788 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11813251 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850240 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850241 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11793795 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11779572 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11801237 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11911370 |
FDA has granted several exclusivities to Qinlock. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Qinlock, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Qinlock.
Exclusivity Information
Qinlock holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Qinlock's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
US patents provide insights into the exclusivity only within the United States, but Qinlock is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qinlock's family patents as well as insights into ongoing legal events on those patents.
Qinlock's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qinlock's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 06, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qinlock Generics:
There are no approved generic versions for Qinlock as of now.
About Qinlock
Qinlock is a drug owned by Deciphera Pharmaceuticals Llc. It is used for treating gastrointestinal stromal tumors in patients who have progressed through multiple lines of treatment, including tyrosine kinase inhibitors like imatinib. Qinlock uses Ripretinib as an active ingredient. Qinlock was launched by Deciphera Pharms in 2020.
Can you believe Qinlock received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Approval Date:
Qinlock was approved by FDA for market use on 15 May, 2020.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Qinlock is 15 May, 2020, its NCE-1 date is estimated to be 15 May, 2024.
Active Ingredient:
Qinlock uses Ripretinib as the active ingredient. Check out other Drugs and Companies using Ripretinib ingredient
Treatment:
Qinlock is used for treating gastrointestinal stromal tumors in patients who have progressed through multiple lines of treatment, including tyrosine kinase inhibitors like imatinib.
Dosage:
Qinlock is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Prescription | ORAL |